Search research articles
Contact Us
Filters
Showing results (61-70 of 110) with videos related to
Page
of 11
Sort By:
Cancer Chemotherapy and Pharmacology
|
November 19, 2013
A phase I trial of flavopiridol in relapsed multiple myeloma
Craig C Hofmeister, Ming Poi, Mindy A Bowers, et al.
Cell Reports
|
June 24, 2014
The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells
Tiffany Hughes, Edward L Briercheck, Aharon G Freud, et al.
American Journal of Hematology
|
August 21, 2013
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma
Jeffrey A Jones, Amy S Rupert, Ming Poi, et al.
Leukemia & Lymphoma
|
June 12, 2024
Impact of chronic graft-<i>versus</i>-host disease on non-relapse mortality and survival
Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, et al.
Journal of Geriatric Oncology
|
July 10, 2018
Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant
Ashley E Rosko, Ying Huang, Don M Benson, et al.
Blood
|
June 26, 2009
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagné, Pascale André, Pieter Spee, et al.
Cancer Immunology, Immunotherapy : CII
|
October 29, 2013
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M Collins, Courtney E Bakan, Gina D Swartzel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 14, 2009
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
Mehdi Hamadani, William Blum, Gary Phillips, et al.
Blood
|
March 12, 2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S Kahl, Stephen E Spurgeon, Richard R Furman, et al.
Leukemia & Lymphoma
|
July 4, 2015
Tocilizumab for steroid refractory acute graft-versus-host disease
Julianna V F Roddy, Bradley M Haverkos, Ali McBride, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 110) with videos related to
Sort By:
Page
of 11
Cancer Chemotherapy and Pharmacology
|
November 19, 2013
A phase I trial of flavopiridol in relapsed multiple myeloma
Craig C Hofmeister, Ming Poi, Mindy A Bowers, et al.
Cell Reports
|
June 24, 2014
The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells
Tiffany Hughes, Edward L Briercheck, Aharon G Freud, et al.
American Journal of Hematology
|
August 21, 2013
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma
Jeffrey A Jones, Amy S Rupert, Ming Poi, et al.
Leukemia & Lymphoma
|
June 12, 2024
Impact of chronic graft-<i>versus</i>-host disease on non-relapse mortality and survival
Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, et al.
Journal of Geriatric Oncology
|
July 10, 2018
Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant
Ashley E Rosko, Ying Huang, Don M Benson, et al.
Blood
|
June 26, 2009
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagné, Pascale André, Pieter Spee, et al.
Cancer Immunology, Immunotherapy : CII
|
October 29, 2013
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M Collins, Courtney E Bakan, Gina D Swartzel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 14, 2009
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
Mehdi Hamadani, William Blum, Gary Phillips, et al.
Blood
|
March 12, 2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S Kahl, Stephen E Spurgeon, Richard R Furman, et al.
Leukemia & Lymphoma
|
July 4, 2015
Tocilizumab for steroid refractory acute graft-versus-host disease
Julianna V F Roddy, Bradley M Haverkos, Ali McBride, et al.
Page
of 11